Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1.
暂无分享,去创建一个
H. Goto | T. Hattori | M. Takeuchi | T. Kezuka | Y. Usui | M. Usui | Youko Okunuki
[1] A. A. Brian,et al. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing , 1994, Cancer Immunology, Immunotherapy.
[2] A. Mackensen,et al. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.
[3] C. Shields,et al. CONTINUING CHALLENGES IN THE MANAGEMENT OF RETINOBLASTOMA WITH CHEMOTHERAPY , 2004, Retina.
[4] G. Chantada,et al. Results of a prospective study for the treatment of retinoblastoma , 2004, Cancer.
[5] M. Weller,et al. Expression of the B7‐related molecule ICOSL by human glioma cells in vitro and in vivo , 2003, Glia.
[6] M. Weller,et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. , 2003, Cancer research.
[7] J. Cheville,et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.
[8] T. Curiel,et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.
[9] Yoshimasa Tanaka,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[10] E. J. Friedman. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. , 2002, Current pharmaceutical design.
[11] G. Freeman,et al. PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2 , 2002, European journal of immunology.
[12] M. Madigan,et al. Immunoglobulin superfamily expression in primary retinoblastoma and retinoblastoma cell lines. , 2002, Oncology research.
[13] G. Zhu,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[14] Ping Lu,et al. B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8+ T Lymphocytes In Vivo , 2001, The Journal of experimental medicine.
[15] J. Gribben,et al. Phase I study of recombinant human CD40 ligand in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] C. Chambers. The expanding world of co-stimulation: the two-signal model revisited. , 2001, Trends in immunology.
[17] J. Egen,et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.
[18] G. Freeman,et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.
[19] F. Gejyo,et al. Cancer immunogene therapy. , 2001, Archivum immunologiae et therapiae experimentalis.
[20] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[21] A. van Elsas,et al. Costimulatory wars: the tumor menace. , 2000, Current opinion in immunology.
[22] F. Lee,et al. Constitutive Expression of Functional 4-1BB (CD137) Ligand on Carcinoma Cells1 , 2000, The Journal of Immunology.
[23] D. Taub,et al. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. , 2000, Molecular immunology.
[24] F. Ionna,et al. CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth. , 2000, International immunology.
[25] G. Alvord,et al. Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.
[26] S. Baldus,et al. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. , 1999, Journal of immunology.
[27] J. Simon,et al. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. , 1999, Cancer research.
[28] J. O'Brien. Alternative treatment in retinoblastoma. , 1998, Ophthalmology.
[29] R. Flavell,et al. CD40 and CD154 in cell-mediated immunity. , 1998, Annual review of immunology.
[30] B. Ksander,et al. Gene transfer of the CD80 costimulatory molecule into ocular melanoma cells using a novel episomal vector. , 1997, Investigative Ophthalmology and Visual Science.
[31] Kazunori Kato,et al. Adoptive transfer of cytotoxic T lymphocytes induced by CD86-transfected tumor cells suppresses multi-organ metastases of C1300 neuroblastoma in mice , 1997, Cancer Immunology, Immunotherapy.
[32] M. Madigan,et al. Human retinoblastoma: in vitro differentiation and immunoglobulin superfamily antigen modulation by retinoic acid , 1997, Cancer Immunology, Immunotherapy.
[33] M. Madigan,et al. Human retinoblastoma: a morphological study of apoptotic, leukocytic, and vascular elements. , 1997, Ultrastructural pathology.
[34] F. Ferris,et al. A new era for the treatment of retinoblastoma. , 1996, Archives of ophthalmology.
[35] J. Suttles,et al. The many roles of CD40 in cell-mediated inflammatory responses. , 1996, Immunology today.
[36] T. Mosmann,et al. The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.
[37] E. Jaffee,et al. A reassessment of the role of B7-1 expression in tumor rejection , 1995, The Journal of experimental medicine.
[38] S. Rosenberg,et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. , 1995, Cancer research.
[39] G. Gray,et al. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. , 1995, Cancer gene therapy.
[40] J. Gribben,et al. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. , 1994, Blood.
[41] T. Springer,et al. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[42] J. Mulé,et al. Experimental and clinical studies of cytokine gene-modified tumor cells. , 1994, Human gene therapy.
[43] P. Bruggen,et al. Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.
[44] S. Barez,et al. Modulation of major histocompatibility complex class 1 genes in human retinoblastoma cells by interferons. , 1993, Investigative ophthalmology & visual science.
[45] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[46] M. Arlen. Tumor antigens. , 1981, The New England journal of medicine.
[47] D. Albert,et al. Characteristics of an established cell line of retinoblastoma. , 1974, Journal of the National Cancer Institute.